Menu

Study: Toddlers of Obese Parents More Susceptible to Developmental Delays

Children born to obese parents are at increased risk of failing motor development and cognitive tests, according to an NIH-led study.

Jan 4, 2017
Ben Andrew Henry

PIXABAY, BETH L.

Overweight parents could be at risk of having children with impaired development, according to a study published January 3 in Pediatrics. Researchers found that children whose parents were substantially overweight were more likely to fail developmental tests for fine motor skills, social competence, or cognitive problem-solving.

The study is also one of the first to examine the effects of not just maternal weight, but paternal weight, on child development. “Our results suggest that dad’s weight also has significant influence on child development,” Edwina Yeung of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes for Health, said in a press release.

Yeung and colleagues analyzed the results of a development survey of nearly 5,000 children. After accounting for factors such as age, race, and education, the researchers found that children with obese mothers were almost 70 percent more likely to fail a test for fine motor skills—dexterously moving their fingers, for instance—at age 3. Children with obese fathers were more likely to fail a test for social interaction. When both parents were overweight, children were at risk of also failing problem-solving tests.

The authors point to obesity-associated inflammation and its possible effects on a developing fetus as one possible mechanism that deserves further study. But they stress that “our study wasn’t designed to prove cause and effect,” Yeung told CNN. “At this point, we only have correlations between parents’ BMI and children's scores on a screening questionnaire.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.